HURA

TuHURA is a clinical-stage immuno-oncology company with zero product revenue and a stack of unproven, binary programs: lead candidate IFx2.0 entered a single randomized placebo-controlled Phase 3 registration trial in Merkel cell carcinoma (adjunctive to Keytruda) only in June 2025, alongside an acquired VISTA antibody (TBS-2025, via the June 2025 Kineta merger) still headed for Phase 1b/2 and a preclinical DOR/ADC platform. None of this generates cash, and the value of the equity rests entirely on trial readouts that the filing itself warns 'may be materially different from what we expect.' This is an unknowable, all-or-nothing outcome, not an investable fundamentals story.

The balance sheet is the disqualifier. FY2025 operating cash burn was -$27.6M while cash and equivalents fell 71.4% to just $3.62M — well under two months of runway at the current spend rate. Current assets of $4.62M (down 76.4%) are already below current liabilities of $5.92M, i.e. negative working capital, and R&D climbed 54% to $20.5M as the Phase 3 ramps. With only $3.62M in the bank against a $28M annual burn, the company must raise capital imminently; the FY2025 share count already jumped 45.6% to 63.6M, so existing holders face heavy, near-certain further dilution simply to keep the lights on and fund the trial.